Poor prognosis acute myelogenous leukemia 2 - Biological and molecular biological characteristics and treatment outcome

Biaoru Li, Jie Yang, Ming Tao, Jaya Nayini, Erzsebet Horvath, Harpareet Chopra, Peterm Meyer, Paramesaran Venugopal, Harvey D. Preisler

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Biological and molecular biological studies were performed on the marrow cells of 25 patients with poor prognosis AML to both characterize this type of leukemia and to assess the relationship between the parameters which were measured and treatment outcome. Treatment failure associated with high levels of telomerase activity and low levels of IL6 transcripts. Studies of the effects of amifostine on these parameters demonstrated that this agent reduced telomerase activity in aspirates of AML marrows. These data suggest that the beneficial effect associated with the administration of amifostine after the end of chemotherapy is likely, to be due to a reduction in the rate at which the surviving leukemia cells repopulate the marrow. Copyright (C) 2000 Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)777-789
Number of pages13
JournalLeukemia Research
Volume24
Issue number9
DOIs
StatePublished - Sep 1 2000

Keywords

  • AML
  • Amifostine
  • Cytokines
  • Remission induction

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Poor prognosis acute myelogenous leukemia 2 - Biological and molecular biological characteristics and treatment outcome'. Together they form a unique fingerprint.

  • Cite this

    Li, B., Yang, J., Tao, M., Nayini, J., Horvath, E., Chopra, H., Meyer, P., Venugopal, P., & Preisler, H. D. (2000). Poor prognosis acute myelogenous leukemia 2 - Biological and molecular biological characteristics and treatment outcome. Leukemia Research, 24(9), 777-789. https://doi.org/10.1016/S0145-2126(00)00035-7